

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
PAIVI JANNA KUKKOLA

Art Unit: 1611

Examiner: R. Raymond

APPLICATION NO: 09/533,219

FILED: MARCH 23, 2000

FOR: THYROMIMETIC ORGANIC COMPOUNDS

Assistant Commissioner for Patents  
Washington, D.C. 20231RECEIVED  
OCT 25 11:11:00  
10/31/00SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis Corporation.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the documents cited on the attached form(s) PTO-1449.


Copies of these documents are enclosed herewith.

It has been noted that International application WO 00/51971 published September 8, 2000 (U.S. priority application 60/122,292 filed March 1, 1999) discloses subject matter which overlaps with subject matter disclosed in the instant application, with respect to the compounds of formula I of WO 00/51971 wherein W is O or S(O)<sub>n</sub>, and R<sup>4</sup> is -S(O)<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, -C(O)NR<sup>9</sup>R<sup>10</sup> or -S(O)<sub>n</sub>R<sup>12</sup>. However, it is believed not to be available as a reference against the instant application which was filed March 23, 2000 and claims the benefit of provisional application 60/183,030 filed March 29, 1999.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6926

  
\_\_\_\_\_  
Norbert Gruenfeld  
Agent for Applicant  
Reg. No. 30,061

Date: October 23, 2000